To quantify the year-to-year variability of altitudeinduced changes in haemoglobin mass (Hb mass ) in elite team-sport athletes.
INTRODUCTION
High variability in physiological and performance responses exists between individuals following live high, train high (LHTH) and live high, train low (LHTL) altitude training. It has been proposed that some individuals respond better than others, possibly due to inherent genetic traits, and that 'responders' and 'non-responders' might explain the high-variability in adaptations to altitude training. [1] [2] [3] [4] [5] Indeed, Chapman et al 4 retrospectively classified a group of distance runners as 'responders' or 'non-responders', based on their change in 5000 m time trial performance, following 28 days of LHTL. These authors 4 reported that athletes who improved their time trial also exhibited the greatest erythropoietin (EPO) response and subsequent changes in red cell volume and VO 2max .
If the classification of 'responder' and 'nonresponder' is a fixed trait, possibly related to underlying genetics, individual athletes should respond similarly whenever undergoing altitude exposure of similar duration and altitude. Only two studies until now 3 5 have investigated the repeatability of responses to altitude. Robertson et al 3 followed eight highly-trained runners during two blocks of hypoxic exposure (3 weeks LHTL), separated by a 5-week washout period, and reported reproducible group mean increases for VO 2max (∼2.1%) and haemoglobin mass (Hb mass (∼2.7%)), but not for mean changes in time trial performance (+0.5% and −0.7% following exposures 1 and 2, respectively). Moreover, there was a moderate but unclear negative correlation for change in Hb mass from one exposure to the next, 3 demonstrating high variability in individual responsiveness between exposures. Similarly, Wachsmuth et al 5 reported a weak correlation (r=0.379, p=0.160) between Hb mass responses following two altitude training camps conducted approximately 3 months apart with elite swimmers, despite very reproducible increases in serum EPO (R=0.95, p<0.001).
Team-sport athletes often complete preseason altitude training camps in an attempt to optimise running performance and we recently reported improved running performance (∼1.5% above matched sea level control) accompanied by a 3.6% increase in Hb mass following 19 days of LHTH in elite team-sport athletes. 6 Similar to previous investigations, 1 2 we reported high variability in erythropoietic responses, which may be partially explained by levels of initial Hb mass 7 ; however, much of this variability remains unexplained. The possible identification of 'responders' and 'non-responders' after a single altitude training camp, or after an acute hypoxic exposure, may allow prescription of altitude training to be targeted towards those athletes who 'respond' well, and/or alternative methods/altitudes adopted in an attempt to enhance the response of potential 'non-responders'.
Therefore, the primary aim of this study was to examine the variability of physiological responses between two similar LHTH preseason training camps in professional Australian-Football players. A secondary aim was to identify potential factors that may influence responsiveness to altitude exposure, such as preintervention Hb mass , energy balance and health status. It was hypothesised that there would be a moderately strong correlation between the magnitude of physiological changes from exposure 1 to exposure 2.
METHODS Subjects
Twelve Australian-Football players completed a 19-day (ALT1) and 18-day (ALT2) moderate altitude (∼2100 m) training camp, separated by
Open Access Scan to access more free content 12 months. Results from ALT1 have been previously reported. 6 An additional 20 participants completed only one of the two training camps (ALT1-additional n=9, ALT2-additional n=11). All training and testing took place during the Australian Football League preseason from November to January, following a 6-week, off-season break. All participants provided written informed consent. All participants were supplemented with oral ferrous sulfate (325 mg/day) throughout the intervention period, and athletes identified as having low serum ferritin preintervention (serum ferritin ≤30 mg/L; n=3) were given a single, 2 mL ferrum H injection (Aspen Pharmacare, St Leonards, Australia; equivalent to 100 mg of iron) prior to the altitude camp.
Training
During ALT1, participants completed an 8-week training block, including 19 days living and training at moderate altitude in Flagstaff, Arizona, USA (elevation ∼2100 m). One year later, participants completed a similar 8-week training block, including 18 days living and training at moderate altitude in Park City, Utah, USA (elevation ∼2000 m). Both training blocks included endurance training, resistance exercise and football specific training (see table 1 ). All training was prescribed by team coaches and monitored through session rating of perceived exertion (RPE). 8 This method calculates a total load (arbitrary units (AU)) by multiplying the session-RPE (Borg's Category Ratio 10-Scale) by the session duration, which is a valid method to quantify training loads in high-intensity, intermittent team sports. 9 
Haematological measures
All participants' Hbmass was measured using the optimised carbon monoxide (CO) rebreathing technique 10 5 days (D −5 ) before altitude exposure (PRE see figure 1 ). Hb mass was measured again one (D 1 ), 13 (D 13 ) and 17 days (D 17 /POST 1 ) after ascent during ALT2 only, and 5 days postdescent (POST 1 ) in ALT1 only. Hb mass was measured again 28 days postdescent in both groups (POST 2 ). Change in Hb mass (ΔHb mass ) was calculated from PRE in ALT1, and from the mean of D −5 and D 1 in ALT2. Briefly, participants rebreathed a bolus of 99% CO equivalent to 1.0 mL/kg of body mass through a glass spirometer (BloodTec, Bayreuth, Germany) for 2 min. Per cent carboxyhaemoglobin (%HbCO) in fingertip capillary blood was measured using the same OSM3 hemoximeter (Radiometer, Copenhagen, Denmark) before and 7 min after administration of the CO dose. CO doses administered at altitude were adjusted for changes in the partial pressure (doses at ∼2000 m equivalent to 1.3 mL/kg). Six repeat measures of %HbCO were made for improved precision in Hb mass estimation. 11 All Hb mass measurements were performed by the same technician. Venous blood samples were collected at PRE, 3 days (D 3 ) and 16 days (D 16 ) after ascent and 13 days postdescent (POST D13 ) in ALT2 only. Samples were centrifuged, serum decanted and frozen at −80°C, and transported to Canberra, Australia for analysis of serum EPO (for ALT2 only), in one batch, using an automated solid-phase, sequential chemiluminescent Immulite assay (Diagnostics Product Corporation, Los Angeles, USA). PRE and POST D13 samples were analysed for reticulocyte count using a Sysmex XE-5000 Automated Haematology Analyser (Roche Diagnostics, Castle Hill, Australia) at St Vincent's Hospital Pathology (Fitzroy, Australia), while D 3 and D 16 samples were analysed using a Sysmex XT-4000i Automated Haematology Analyser (Sysmex, Lincolnshire, USA) at Park City Medical Centre (Park City, USA). Serum ferritin was assessed at PRE using an AU5800 immuno-turbidimetric assay (Beckman Coulter, Lane Cove, Australia) to identify iron-deficient participants.
Body mass and illness
Body mass was monitored daily on waking (07:00-08:00) in a well hydrated state (confirmed through urine specific gravity measures (URC-N E , Atago, Tokyo, Japan)) throughout the intervention period using electronic scales (Tanita, Kewdale, Australia). Changes in body mass were calculated from the first to the last day at altitude during both camps. Athletes were classified as 'ill' if any training session was missed throughout the intervention period due to physical illness, excluding musculoskeletal injuries.
Statistical analysis
A magnitude-based statistical approach 12 was used to detect small effects of practical importance. Data were log-transformed to account for non-uniformity error. Differences within and between groups were assessed with dependent and independent t tests for unequal variance. 12 The magnitude of changes were assessed in relation to the smallest worthwhile change (SWC), set to 2% for Hb mass and a small effect size (d=0.2×the between-participant SD for PRE) for other variables. Observed effects were reported as the mean change or difference ±90% confidence limits. Effects were termed positive, trivial or negative depending on the magnitude of the change relative to the SWC and assigned a qualitative descriptor according to the likelihood of the change exceeding the SWC: 50-74% 'possible', 75-94% 'likely', 95-99% 'very likely', >99% 'almost certainly'. 13 Effects where the 90% CI overlapped simultaneously the substantially positive and negative thresholds were deemed 'unclear'. The magnitude of individual responses were calculated from the square root of the difference in the variance of the change scores.
14 A Pearson's correlation coefficient was used to examine the relationship between percentage change in Hb mass (%ΔHb mass ) from ALT1 to ALT2 and the relationship between initial Hb mass and change in Hb mass . Because one participant's results appeared to heavily influence the relationship from year to year, a Pearson's correlation was also performed after removing these data. Participants who reported illness (ALT1 n=2, ALT2 n=3, total n=5) were removed from correlation analyses, as proinflammatory cytokines suppress EPO production. 15 Participants were also retrospectively divided into groups classified as BodyMass stable (gained mass or lost <2.0 kg), or BodyMass loss (lost >2.0 kg). 
RESULTS

Training load, duration and RPE
Weekly training load, duration and RPE for all participants are presented in table 2A. The overall training load was very likely 5.5 ±4.8% (mean±90% CI) higher and mean RPE almost certainly 7.2±2.6% higher in ALT1 compared to ALT2. Training duration was very likely 12.6±3.6% higher in ALT2 compared to ALT1. The weekly training load, duration and RPE for healthy repeat participants (n=9) are presented in table 3. There was an unclear 0.5±3.5% difference in the overall training load between ALT1 and ALT2. The overall mean RPE was very likely 5.1±2.8% lower and training duration was almost certainly 13.5±2.4% higher in ALT2 compared to ALT1.
Haemoglobin mass
Hb mass (all participants): The typical error of Hb mass for the pooled data of all 32 participants, for measures made approximately 5 days apart, was 2.6% (90% CI of 2.1% to 3.3%). Mean (±SD) Hb mass in ALT1 (n=21) and ALT2 (n=23) groups preintervention was 992±129 and 1008±159 g, respectively. %ΔHb mass from baseline is displayed in figure 2 . Mean % ΔHb mass (±90% CL) was very likely increased at POST 1 in ALT1 (3.6±1.6%, with individual responsiveness of 1.3%) and almost certainly increased at D 13 (3.9±1.0%) and D 17 (4.0 ±1.3%, with individual responsiveness of 2.2%) in ALT2. Differences in %ΔHb mass between ALT1 and ALT2 from PRE to postintervention (POST 1 and D 17 during ALT1 and ALT2, respectively) were unclear (−1.3±7.0%). Hb mass returned to baseline at 4 weeks postaltitude in ALT1 and ALT2. There was a negative correlation (R=−0.51, p=0.04; see figure 3 ) between initial Hb mass relative to body mass (RelHb mass ) and %ΔHb mass at POST 1 in healthy BodyMass stable participants (n=30).
Hb mass (participants completing ALT1 and ALT2): There was a trivial difference in Hb mass at PRE for ALT1 (1023±143 g) Figure 1 Timeline of haemoglobin mass (Hb mass ) collection over ALT1 and ALT2. figure 4 ). After removing one participant who was influencing the results heavily, the correlation between Hb mass from year to year reduced to R=0.02 (n=8, p=0.96, figure 4) . Hb mass (ill vs healthy participants): figure 5A shows % ΔHb mass for participants separated into healthy (n=39) and ill (n=5) groups. Ill participants had a trivial 0.2±2.4% change in Hb mass at POST 1 , which was almost certainly 3.9±1.1% lower than changes in healthy participants. There was a trivial 1.1 ±1.6% difference in Hb mass between ill and healthy participants at POST 2 .
Hb mass (BodyMass stable vs BodyMass loss participants): Changes in body mass and Hb mass and body mass for the BodyMass stable (n=30) and BodyMass loss (n=9) groups are presented in figure  5B , C, respectively. BodyMass loss participants very likely lost 2.6 ±0.9 kg from PRE to POST 1 , while BodyMass stable participants had a trivial 0.2±1.3 kg change in body mass. BodyMass loss participants possibly increased in Hb mass by 2.6±1.8% at POST 1 , which was possibly 2.4±2.1% lower than the changes in the BodyMass stable group. At POST 2 , BodyMass loss participants had a possible 2.3±2.7% decrease in Hb mass from PRE, which was very likely 3.9±1.9% lower than the BodyMass stable group. Figure 6 shows reticulocyte percentage and EPO concentrations for ALT2. Compared with PRE, reticulocytes almost certainly increased by 39±12% at D 3 and very likely increased 16±10% at D16. Reticulocytes almost certainly reduced from PRE by 27±10% at POST D13 . EPO almost certainly increased by 36±10% and 22±10% from PRE at D 3 and D 16 , respectively, and almost certainly reduced from PRE by 16±16% at POST D13 .
Reticulocytes and EPO-for ALT2 only
DISCUSSION
The main finding of the current investigation is that, while two preseason moderate altitude camps yield a similar group mean increase (∼4%) in Hb mass of elite footballers, there is wide variability in this erythropoietic response and individual athletes do not exhibit consistency in changes in Hb mass from year to year. Table 3 Training load, training duration and rate of perceived exertion (mean±SD) for the nine participants completing both ALT1 and ALT2
ALT1 ALT2
Per cent chances for ALT1 to be greater/similar/smaller than the SWC compared with ALT2 Figure 2 Percentage changes in haemoglobin mass (Hb mass ) (mean ±90% CI) after altitude ALT1 and ALT2.
Thus, a 'responder' or 'non-responder' to altitude does not appear to be a fixed trait with respect to changes in Hb mass . Some of the variability in erythropoietic response may be explained by the incidence of illness, reductions in body mass and precamp Hb mass , but large variability is still evident in healthy athletes who maintain body mass. Another important finding is that almost all of the erythropoietic response of an 18-day altitude camp (ALT2) occurred within the first 13 days of exposure.
Repeatability of changes in Hb mass
We previously reported that elite team-sport athletes achieved a mean increase of ∼3.6% in Hb mass over a 19-day altitude camp. 6 During a subsequent 18-day exposure (ALT2), our participants achieved a similar mean increase in Hb mass of 4%. However, in agreement with other work, 1 4 16 there was considerable individual variability in the erythropoietic response. Chapman et al 4 introduced the concept of 'responders' and 'non-responders' to altitude when they found that participants who achieved the greatest improvements in 5000 m running performance following LHTL also demonstrated the greatest erythropoietic response. This led to suggestions that the magnitude of an individual's response to altitude may be influenced by genetically determined traits. 4 17 This theory proposes that individuals should respond similarly on subsequent hypoxic exposures, given the same hypoxic dose (ie, exposure time and degree of hypoxia). However, we observed a small correlation between changes in Hb mass following ALT1 and ALT2 (R=0.21) in participants who completed both training camps (n=9), which was reduced to R=0.02 when the sole outlier was removed. This supports previous investigations 3 5 that have reported weak (R∼0.10-0.38) relationships between changes in Hb mass following repeated altitude exposures ∼1-3 months apart, suggesting that responsiveness to a given hypoxic stimulus is not a fixed trait. The ∼2% typical error of the optimised CO rebreathing technique 10 18 along with natural biological variations 19 20 may, in part, contribute to the variability from exposure to exposure.
Timeline of erythropoietic response
It is well accepted that a sufficient hypoxic dose (h/day; number of days; degree of hypoxia) is required to induce detectable erythropoietic benefit. 21 22 Wilber et al 21 suggested that altitude training at 2000-2500 m for at least 22 h/day and a minimum of 4 weeks is required to optimise physiological benefits. However, these recommendations are based on data from studies that examined erythrocyte volumes pre and postaltitude exposure, with little data addressing the time course of responses. Recently, detectable increases in Hb mass have been reported with exposures as short as 11 23 and 13 days 5 . Similarly, we observed an ∼4% increase in Hb mass after 13 days at altitude, with no additional increases by day 17. This suggests that erythropoietic benefits are possible with shorter duration altitude training camps than commonly recommended, given sufficient altitude/hypoxia. 21 A 2-week time course may have significant implications for team-sport organisations, which often schedule altitude camps during limited preseason periods and may face financial restrictions during longer duration camps due to travel/accommodation costs for athletes and support staff.
Effect of initial RelHb mass
We found a similar relationship between initial RelHb mass and %ΔHb mass as in our original investigation. 6 These data support the work of Robach and Lundby, 7 which suggests that athletes starting with low RelHb mass have the ability to increase Hb mass to a greater extent following hypoxic interventions. Others have proposed that athletes with initially high RelHb mass (∼14.7 g/kg) may have already 'maximised' this component of their physiological capacity through training at sea level, 24 with limited opportunity to further increase Hb mass through altitude interventions. However, subsequent research from the same group showed that increases in Hb mass can be achieved in cyclists possessing elevated initial RelHb mass (∼14.2 g/kg). 23 It is also possible that altitude training interventions may increase Hb mass to a given individual's physiological limit, and responsiveness may therefore vary depending on an individual's baseline Hb mass . 5 Collectively, these data [5] [6] [7] suggest that team-sport athletes with a higher initial RelHb mass may have an attenuated ability to increase Hb mass with altitude training interventions.
Effect of illness on erythropoiesis
It has been suggested that athletes suffering from infection/ illness/injury that results in increased inflammation may have limited erythropoietic responses to altitude exposures. 5 6 Indeed, Wachsmuth et al 5 reported attenuated changes in Hb mass in sick/injured athletes following LHTH interventions at 2320 m. Similarly, we observed an attenuated erythropoietic response in participants experiencing illness during ALT1 (n=2) and ALT2 (n=3) (see figure 5A ). Proinflammatory cytokines, such as interleukin 1(IL-1), are known to suppress the release of EPO, 15 and EPO data for ill participants during ALT2 are highlighted in figure 6B . Participants (b) and (c) (in figure 6B) suffered illness immediately preceding the camp, which was accompanied by low EPO levels before and throughout the camp duration. Participant (a) fell ill on arriving at a high altitude and displayed suppressed EPO responses thereafter. Making statistical inferences are difficult, given that instances of illness/injury are low in our investigation (n=5) and in Wachsmuth et al 5 (n=7) . However, these data support the hypothesis that illness/injury may limit the erythropoietic benefits associated with prolonged hypoxic exposures.
Effect of body mass reductions on erythropoiesis
Participants experiencing reductions in body mass (>2 kg) achieved approximately half of the erythropoietic benefit as those maintaining body mass (∼2.5% vs ∼5% increase in Hb mass , respectively). Furthermore, at 4 weeks postaltitude, BodyMass loss participants displayed Hb mass ∼2.3% below prealtitude levels. Our results are in contrast with those of Gough et al, 25 who modelled that body mass changes over approximately 6 months did not significantly alter Hb mass ; for instance, that a 10% loss of body mass would only decrease Hb mass by 1.4%. In contrast, the 2.6 kg reduction in body mass within the Australian-Footballer subgroup over 18-19 days suggests a mismatch between energy consumption and energy expenditure and thus an overall catabolic state, which may not support an anabolic process like erythropoiesis. Evidence in maintenance haemodialysis patients with haemodialysis suggests that poor appetite and low protein intake are associated with increased serum concentrations of inflammatory markers (including C reactive protein, IL-6 and tumour necrosis factor-α) and increased synthetic EPO dose requirements. 26 While mechanisms for a poor erythropoietic response in BodyMass loss participants are not clear, the combination of altitude exposure and weight loss appears to be counterproductive for Hb mass maintenance.
Limitations
This research was conducted with a relatively small sample of elite Australian-Football players. Even when using a magnitudebased statistical approach, 12 the small sample size limitations are most apparent in our attempts to quantify the effects of initial Hb mass , as well as loss of body mass and of illness on the response to altitude. A further limitation is the use of two different Sysmex haematology analysers for the reticulocyte measures, since even Sysmex analysers that are calibrated within the manufacturer's tolerances can have biases of the order of 0.3-0.5% reticulocytes. 27 The applied nature of this research also led to a number of limitations, which should be considered when interpreting our results. ALT1 and ALT2 were conducted in different locations over different durations (19 and 18 days, respectively). However, the altitude at these locations is very similar (∼2100 m) and the overall hypoxic dose between camps differed by only 18 h. The temporal measurements of Hb mass differed between ALT1 and ALT2; POST 1 was taken 5 days postaltitude (ALT1) compared with the penultimate day at altitude (ALT2). Therefore, the potential confounding effects of neocytolysis upon return to sea level 23 28 during ALT1 may account for some of the variability between the two exposures.
CONCLUSION
This investigation was conducted in an ecologically valid environment, with professional team-sport athletes engaging in preseason altitude training in an attempt to improve subsequent performance at sea level. As responsiveness to a given altitude exposure does not appear to be a fixed trait, it is not currently possible for individual athletes to be identified as 'responders' or 'non-responders' following a single altitude exposure. To optimise the erythropoietic benefit from an LHTH intervention, athletes should be well prepared, in good health and maintain body mass throughout its duration. Healthy team-sport athletes should expect a 3-4% increase in Hb mass following an 18-19 day altitude training camp, with this erythropoietic response possibly achievable in as short as 13 days. What are the new findings ▸ Team sport athletes produce repeatable group mean increases in Hb mass (∼4%) over 18-19 day moderate altitude camps, and these benefits may be achieved in as short as 13 days. ▸ Individual athletes do not exhibit consistency in altitude-induced changes in Hb mass from year to year, and thus a 'responder' or 'non-responder' to altitude does not appear to be a fixed trait. ▸ To achieve full erythropoietic benefit from altitude exposure, athletes should maintain body mass and remain free from illness immediately before and throughout the exposure.
How might it impact on clinical practice in the near future?
▸ Athletes may gain physiological benefits from participating in shorter duration (∼13 days) altitude training camps than previously recommended. ▸ Strategies to maintain body mass and optimal health immediately before and throughout altitude training camps should be adopted.
